Citi analyst Andrew Baum raised his price target for Merck to $84 and reiterates a Buy rating on the shares. The analyst says his 20%-plus above consensus non-GAAP earnings estimates beyond 2022 are driven by a continued view that the market underestimates Merck’s market share in the PDx and PARP spaces with Keytruda and Lynparza respectively.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.